Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 530.98Cr 79Cr 68Cr 64Cr 58Cr 110.28Cr 7.5TCr 111.98Cr 749.72Cr 294.24Cr 3.74TCr 295.22Cr 288.73Cr 13TCr P/E 2026 *
5.56x
P/E 2027 * 4.95x
Enterprise Value 530.98Cr 79Cr 68Cr 64Cr 58Cr 110.28Cr 7.5TCr 111.98Cr 749.72Cr 294.24Cr 3.74TCr 295.22Cr 288.73Cr 13TCr EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.63x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
3 years 18.53
Extreme 18.53
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 01/12/2019
Comptroller/Controller/Auditor 53 01/02/2011
Director TitleAgeSince
Chairman 70 14/08/2002
Director/Board Member 62 14/08/2002
Director/Board Member 58 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.89%-.--% - - 80Cr
-0.53%+1.87%+14.81%+74.83% 5.03TCr
-1.81%+1.69%+53.40%+106.05% 3.72TCr
+0.46%+5.76%-5.53%+25.08% 1.24TCr
+1.05%+1.17%+13.23%+75.93% 1.17TCr
-1.14%+0.57%+32.24%+132.30% 916.74Cr
-2.99%-0.60%+43.05%-8.54% 724.23Cr
+0.51%+1.29%+14.45%+34.63% 679.97Cr
+1.99%+1.31%+3.73%+179.67% 647.44Cr
+0.39%-4.81%-34.14%-1.07% 546.45Cr
Average +0.18%+1.96%+15.03%+68.76% 1.63TCr
Weighted average by Cap. -0.59%+2.71%+22.91%+78.05%

Financials

2026 *2027 *
Net sales 303.39Cr 45Cr 39Cr 36Cr 33Cr 63Cr 4.29TCr 64Cr 428.38Cr 168.12Cr 2.13TCr 168.68Cr 164.98Cr 7.16TCr 326.3Cr 48Cr 42Cr 39Cr 36Cr 68Cr 4.61TCr 69Cr 460.73Cr 180.82Cr 2.3TCr 181.42Cr 177.43Cr 7.7TCr
Net income 96Cr 14Cr 12Cr 11Cr 11Cr 20Cr 1.35TCr 20Cr 134.97Cr 53Cr 672.54Cr 53Cr 52Cr 2.26TCr 107.2Cr 16Cr 14Cr 13Cr 12Cr 22Cr 1.51TCr 23Cr 151.36Cr 59Cr 754.22Cr 60Cr 58Cr 2.53TCr
Net Debt - -
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,822
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
7.029CNY
Average target price
7.943CNY
Spread / Average Target
+13.00%

Quarterly revenue - Rate of surprise